A metabolomic analysis conducted by Kim et al. on genetically engineered mouse models combining oncogenic KRAS with LKB1 mutations revealed the activation of the HBP pathway in NSCLC [35]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.